G.J Hofmeyr , Z Alfirevic , B Matonhodze , P Brocklehurst , E Campbell , V.C Nikodem
{"title":"Titrated oral misoprostol solution for induction of labour: a multi-centre, randomised trial","authors":"G.J Hofmeyr , Z Alfirevic , B Matonhodze , P Brocklehurst , E Campbell , V.C Nikodem","doi":"10.1016/S0306-5456(01)00231-5","DOIUrl":null,"url":null,"abstract":"<div><p><strong>Objectives</strong> To determine the effects of titrated oral misoprostol solution, compared with vaginal dinoprostone.</p><p><strong>Study design</strong> Open, randomised clinical trial.</p><p><strong>Setting</strong> Academic hospitals in South Africa and Liverpool, UK.</p><p><strong>Methods</strong> Women undergoing induction of labour after 34 weeks of pregnancy were allocated by randomised, sealed opaque envelopes, to induction of labour with titrated oral misoprostol solution, or two doses of vaginal dinoprostone (2mg) administered six hours apart. Failure to deliver within 24 hours of randomisation was the primary outcome on which the sample size was based. The data were analysed by intention-to-treat.</p><p><strong>Results</strong> Six hundred and ninety-five women were randomly allocated: 346 to oral misoprostol and 349 to vaginal dinoprostone. There were no significant differences in substantive outcomes. Vaginal delivery within 24 hours was not achieved in 38% of women in the oral misoprostol group and 36% in the vaginal dinoprostone group (RR 1.08; 95% CI 0.89-1.31). The caesarean section rates were 16% and 20%, respectively (RR 0.80; 95% CI 0.58-1.11). Hyperstimulation with fetal heart rate changes occurred in 4% of women in the oral misoprostol group and 3% after vaginal dinoprostone (RR 1.32, 95% CI 0.59–2.98). The response to induction of labour in women with unfavourable cervices was somewhat slower with misoprostol when membranes were intact, and with dinoprostone when membranes were ruptured. There were no differences in neonatal outcome between the two groups.</p><p><strong>Conclusions</strong> This new approach to oral misoprostol administration was successful in minimising the risk of uterine hyperstimulation, which has been a feature of misoprostol use for induction of labour, at the expense of a somewhat slower response in women with intact membranes and unfavourable cervices. Misoprostol is not registered for use in pregnant women, and further research is needed to confirm optimal and safe dosages.</p></div>","PeriodicalId":75620,"journal":{"name":"British journal of obstetrics and gynaecology","volume":"108 9","pages":"Pages 952-959"},"PeriodicalIF":0.0000,"publicationDate":"2001-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0306-5456(01)00231-5","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of obstetrics and gynaecology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306545601002315","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives To determine the effects of titrated oral misoprostol solution, compared with vaginal dinoprostone.
Study design Open, randomised clinical trial.
Setting Academic hospitals in South Africa and Liverpool, UK.
Methods Women undergoing induction of labour after 34 weeks of pregnancy were allocated by randomised, sealed opaque envelopes, to induction of labour with titrated oral misoprostol solution, or two doses of vaginal dinoprostone (2mg) administered six hours apart. Failure to deliver within 24 hours of randomisation was the primary outcome on which the sample size was based. The data were analysed by intention-to-treat.
Results Six hundred and ninety-five women were randomly allocated: 346 to oral misoprostol and 349 to vaginal dinoprostone. There were no significant differences in substantive outcomes. Vaginal delivery within 24 hours was not achieved in 38% of women in the oral misoprostol group and 36% in the vaginal dinoprostone group (RR 1.08; 95% CI 0.89-1.31). The caesarean section rates were 16% and 20%, respectively (RR 0.80; 95% CI 0.58-1.11). Hyperstimulation with fetal heart rate changes occurred in 4% of women in the oral misoprostol group and 3% after vaginal dinoprostone (RR 1.32, 95% CI 0.59–2.98). The response to induction of labour in women with unfavourable cervices was somewhat slower with misoprostol when membranes were intact, and with dinoprostone when membranes were ruptured. There were no differences in neonatal outcome between the two groups.
Conclusions This new approach to oral misoprostol administration was successful in minimising the risk of uterine hyperstimulation, which has been a feature of misoprostol use for induction of labour, at the expense of a somewhat slower response in women with intact membranes and unfavourable cervices. Misoprostol is not registered for use in pregnant women, and further research is needed to confirm optimal and safe dosages.
目的比较口服米索前列醇滴定溶液与阴道迪诺前列酮的疗效。研究设计:开放、随机临床试验。在南非和英国利物浦设立学术医院。方法对妊娠34周后进行引产的妇女采用随机、密封的不透明包膜进行分组,分别给药米索前列醇滴定口服溶液或阴道二诺前列酮(2mg),间隔6小时。未能在随机化24小时内交付是样本量所基于的主要结果。通过意向治疗对数据进行分析。结果695名妇女随机分配:口服米索前列醇组346名,阴道迪诺前列酮组349名。在实质性结果上没有显著差异。口服米索前列醇组和阴道诺前列醇组分别有38%和36%的妇女未能在24小时内实现阴道分娩(RR 1.08;95% ci 0.89-1.31)。剖宫产率分别为16%和20% (RR 0.80;95% ci 0.58-1.11)。口服米索前列醇组和阴道迪诺前列醇组分别有4%和3%的女性出现过度刺激和胎儿心率改变(RR 1.32, 95% CI 0.59-2.98)。胎膜完好时使用米索前列醇,胎膜破裂时使用迪诺前列酮,对胎位不利的妇女引产反应稍慢。两组新生儿结局无差异。结论:这种口服米索前列醇的新方法成功地将子宫过度刺激的风险降至最低,这是米索前列醇用于引产的一个特点,但代价是对膜完整和服务不利的妇女的反应较慢。米索前列醇未注册用于孕妇,需要进一步的研究来确认最佳和安全的剂量。